You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
BCR::ABL1 screening is not indicated in patients with splenomegaly without neutrophilia and/or basophilia
  1. Stephen E Langabeer
  1. Cancer Molecular Diagnostics, Saint James's Hospital, Dublin, Ireland
  1. Correspondence to Dr Stephen E Langabeer, Cancer Molecular Diagnostics, Saint James's Hospital, Dublin, D08 W9RT, Ireland; slangabeer{at}stjames.ie

https://doi.org/10.1136/jcp-2023-208864

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The underlying causes of splenomegaly are myriad and include acute, chronic and tropical infections; haematological malignancies (both acute and chronic, myeloid and lymphoid); non-neoplastic haematological conditions (thalassaemia, autoimmune haemolysis); congestive causes (cirrhosis, cardiac failure); inflammatory conditions (systemic lupus erythematosus, sarcoidosis); neoplastic causes (haemangioma, metastases) and infiltrative processes (Gaucher’s disease, amyloidosis).1 Chronic myeloid leukaemia (CML) is a haematopoietic stem cell–derived myeloproliferative neoplasm, molecularly characterised by the presence of the BCR::ABL1 oncogene and which has become the paradigm for molecularly targeted therapy in oncology. The common …

    View Full Text

    Footnotes

    • Handling editor Vikram Deshpande.

    • Contributors SEL conceived, handled and wrote the data and authorised the submission.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.